Healthcare Archives

PTSD in Multi-Plaintiff and Mass Tort Cases | Webinar OnDemand
Gallery
PTSD in Multi-Plaintiff and Mass Tort Cases | Webinar OnDemand

PTSD in Multi-Plaintiff and Mass Tort Cases | Webinar OnDemand

July 19th, 2019|Categories: Complex Business Litigation, HB Risk Notes, Mass Torts|Tags: employment law, Expert Witnesses, Healthcare, Litigation & appeals, mass torts|

[one-fourth-first] Price: $47 When: On-demand Where: Your computer or mobile device CLE: 1 hour Speakers Mark I. Levy MD, DLFAPA Medical Director Forensic Psychiatric Associates Medical Corporation Associate Clinical Professor, Psychiatry University of California, San Francisco, School of Medicine 415.388.8040 mlevy@fpamed.com Sarah A. Hall, PhD. Psychologist for Forensic & Neuropsychological Assessments Forensic Psychiatric Associates Medical Corporation shall@fpamed.com [/one-fourth-first][three-fourths] What tort attorneys need to know about PTSD claims. Mass tort claims arise most frequently in man-made and natural disaster catastrophe litigation as well as personal injury, employment, product liability and toxic tort litigation. Frequently, these lawsuits include either primary or secondary allegations of emotional distress. PTSD is one of the most common emotional distress claims alleged within mass tort litigation, as well as allegations of depression and emotional stress (anxiety). Join an experienced psychiatrist and psychologist who will cover the following topics relevant to the forensic psychiatric assessment of emotional damages within mass tort and complex litigation: + Introduction: Defining PTSD. What it is and what it is not. + The methodological approach to assessing allegations of emotional distress in mass tort & complex litigation. + The importance and the methodology of psychological testing as part of the assessment of emotional distress claims in mass tort litigation. + Claimant population screening. Using psychological test instruments to differentiate claimants who [...]

Dr. Babyl: Artificial Intelligence Could Save Lives, Time and Money — TheDailyBeast.com

May 27th, 2019|Categories: Corporate Compliance, HB Risk Notes, Technology Law|Tags: Artificial Intelligence (AI), cybersecurity, data analytics, data privacy, Healthcare|

Itchy throat? Headache? Upset stomach? There's an app for that. There is a new AI healthcare system called Babylon UK’s National Health Service which features an AI-driven app that is reportedly able to separate “run-of-the-mill” illnesses from more life-threatening ones, while saving time, money, and anxiety for patients and doctors alike. Babylon offers more than diagnostic assistance; it is accessible to people in remote areas. "For example, Babyl, the Rwandan version of Babylon, offers remote appointments with clinicians, fills prescriptions, orders lab tests, and issues referrals.” Babyl enables affordable, personalized healthcare, combined with “the brains of thousands of doctors at once” to reach patients who cannot get to a doctor’s officer. In addition to assisting doctors with everyday check-ups and treating the common cold, the AI’s abilities extend to clinical trials. “In 2018 the Mayo Clinic partnered with IBM’s Watson to match patients with breast cancer to accessible clinical trials covered by their health plans. The matching program increased the enrollment of breast cancer sufferers in Mayo Clinic’s own clinical trials by 80%." Questions are being raised, however, about how to mitigate risks posed by hacking or by nefarious manipulation of the system. Read about this and more in the complete post by Joelle Renstrom on TheDailyBeast.com.

Attorney General Ferguson of Washington Sues State’s Top Opioid Distributers

March 20th, 2019|Categories: Class Actions, Emerging Litigation & Risk, HB Risk Notes, HB Tort Notes, Mass Torts|Tags: class actions, Drug Laws, Drugs & Devices, Healthcare, mass torts|

“We are woefully under-resourced when it comes to treatment. The people who are responsible for this epidemic should being paying for it. We are going to hold these companies accountable and get more money into our communities for treatment.” --Washington AG Bob Ferguson The three largest distributors of prescription opioids in Washington State are being sued by Attorney General Bob Ferguson for fueling the state's opioid epidemic. Detailed in Ferguson's King County lawsuit are the billions of dollars made from these suspicious shipments of over 2 billion pills of unregulated oxycodone, fentanyl, hydrocodone and other opioids. "Prescriptions and sales of opioids in Washington skyrocketed more than 500 percent between 1997 and 2011. In 2011, at the peak of overall sales in Washington, more than 112 million daily doses of all prescription opioids were dispensed in the state — enough for a 16-day supply for every woman, man and child in Washington," according to the AG's announcement. "In 2014 McKesson, Cardinal Health and AmerisourceBergen shipped enough opioids to Pend Orielle County to supply every single resident with dozens of pills. In 2009, McKesson alone supplied enough for dozens of pills for every resident of the county. The specific shipment numbers are currently under seal." The accused distributors are in the top 15 Fortune 500 list based on 2017 revenue. In addition to the [...]

Stigma and Shame Hampered AIDS Treatment in the 80s, and Opioid Treatment Today

January 2nd, 2019|Categories: Class Actions, HB Risk Notes, HB Tort Notes, Insurance|Tags: class actions, Healthcare, healthcare fraud, insurance, Liability Claims|

By Tom Hagy I worked in the press office of the New Jersey Department of Health in the 1980s. Aside from hazardous waste, asbestos, cancer, a chemical fire or two, the annual influenza "crisis" and the occasional salmonella outbreak, AIDS was one of the most urgent, frightening and misunderstood health issues of the day. The U.S. epidemic began with one reported case in 1981, according to the Centers for Disease Control, and grew to an astounding 36.9 million people living with HIV/AIDS in 2017 as reported by the World Health Organization. The office I worked in was tasked with providing information to the public and members of the press. At the time many public health professionals believed -- as is the case with many diseases -- that education on how to prevent transmission of the HIV virus would all but eliminate its spread. All we had to do was educate the public and, most importantly, the high-risk groups. Education is a common weapon in fighting disease. It's why we wash our hands, cough into our elbows and try not to put salt on absolutely everything we put in our mouths. In the early 1980s the "problem" was that the high-risk groups were having homosexual sex and injecting drugs -- not typical themes addressed by politicians. Early on more conservative policymakers didn't [...]

Artificial Intelligence in the Drug and Device Industries

August 9th, 2018|Categories: Complex Business Litigation, HB Tort Notes, Technology Law|Tags: Artificial Intelligence (AI), data analytics, emerging litigation, Healthcare, Life Sciences|

Are Data Divers and Miners Going to Lead Innovation? The big tech companies are into it. Apple, IBM and Google. Roche is into it. Medtronic, as well. Artificial intelligence has been a big part of innovation in the healthcare space for several years, and its impact is only going to get bigger. "Artificial intelligence-based healthcare technologies have contributed to improved drug discoveries, tumor identification, diagnosis, risk assessments, electronic health records (EHR), and mental health tools, among others," writes Blank Rome attorney Brian Higgins in his Artificial Intelligence and the Law Blog (it's excellent, by the way). [1] Daniel Faggella of TechEmergence.com writes that machine learning healthcare applications are getting a lot of attention in the press and from the investment community. He adds to the list of machine learning's impact things like treatment queries and suggestions, and even robotic surgery. But optimism for AI's application to drug discovery seems greater than that inspired by other healthcare sectors. One reason for that, Faggella writes, is that compared to other segments where various laws and stakeholder incentives may not align, "drug discovery stands out as a relatively straightforward economic value for machine learning healthcare application creators." He adds that this application also involves "one relatively clear customer who happens to generally have deep pockets: drug companies." [2] Also writing for TechEmergence.com, Kumba Sennaa says [...]